Quoin Pharmaceuticals announces FDA granted RPD designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease, RPD, Designation for the Company’s lead asset, QRX003, for the treatment of Netherton Syndrome. The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency, EMA, which granted Orphan Drug Designation to QRX003 in May 2025.